Vertex Pharmaceuticals IncorporatedVRTXNASDAQ
Loading
Net Income Growth Recovery in ProgressRecovering
Percentile Rank59
Year-over-Year Change
Year-over-year net income growth rate
Latest
9.99%
↓ 87% vs avg
Percentile
P59
Within normal range
Streak
1 qtr
Consecutive growthRecovering
Average
77.22%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | 9.99% |
| Q3 2025 | 4.84% |
| Q2 2025 | 59.82% |
| Q1 2025 | -29.21% |
| Q4 2024 | -12.67% |
| Q3 2024 | 129.09% |
| Q2 2024 | -426.81% |
| Q1 2024 | 13.50% |
| Q4 2023 | -6.42% |
| Q3 2023 | 13.06% |
| Q2 2023 | 30.85% |
| Q1 2023 | -14.54% |
| Q4 2022 | -11.99% |
| Q3 2022 | 14.81% |
| Q2 2022 | 6.35% |
| Q1 2022 | -1.04% |
| Q4 2021 | -9.61% |
| Q3 2021 | 1172.98% |
| Q2 2021 | -89.75% |
| Q1 2021 | 8.10% |
| Q4 2020 | -9.48% |
| Q3 2020 | -20.28% |
| Q2 2020 | 38.91% |
| Q1 2020 | 3.35% |
| Q4 2019 | 914.00% |
| Q3 2019 | -78.49% |
| Q2 2019 | -0.45% |
| Q1 2019 | -82.67% |
| Q4 2018 | 1104.33% |
| Q3 2018 | -37.91% |
| Q2 2018 | -1.38% |
| Q1 2018 | 108.83% |
| Q4 2017 | 197.80% |
| Q3 2017 | -672.08% |
| Q2 2017 | -92.74% |
| Q1 2017 | 652.03% |
| Q4 2016 | 178.74% |
| Q3 2016 | 35.16% |
| Q2 2016 | -54.99% |
| Q1 2016 | 44.87% |